Seres Therapeutics Inc (MCRB)

May 28, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of “Reduce” by Brokerages - Defense World

May 28, 2025

May 27, 2025

Seres Therapeutics reports promising biomarker data By Investing.com - Investing.com South Africa

May 27, 2025

May 27, 2025

Seres Therapeutics (MCRB) to Present New Biomarker Data at ASCO 2025 | MCRB Stock News - GuruFocus

May 27, 2025

May 27, 2025

Seres Therapeutics reports promising biomarker data - Investing.com

May 27, 2025

May 27, 2025

Seres Therapeutics to Present New Biomarker Data from SER-155 Phase 1b Study at 2025 ASCO Annual Meeting - Nasdaq

May 27, 2025

May 27, 2025

Breakthrough: Seres Therapy Cuts Deadly Infection Risk by 77% in Cancer Transplant Patients, ASCO Data Shows - Stock Titan

May 27, 2025

May 23, 2025

Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

May 23, 2025

May 17, 2025

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - Defense World

May 17, 2025

May 16, 2025

Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade - NewsBreak: Local News & Alerts

May 16, 2025

May 12, 2025

Human Microbiome Market Forecast: Growth Trends, Key Players & - openPR.com

May 12, 2025

May 11, 2025

Seres Therapeutics’ (MCRB) “Neutral” Rating Reiterated at Chardan Capital - Defense World

May 11, 2025

May 09, 2025

StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold - Defense World

May 09, 2025

May 08, 2025

Seres Therapeutics Shares Fall After Downgrade From Chardan - marketscreener.com

May 08, 2025

May 08, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript - Insider Monkey

May 08, 2025

May 08, 2025

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga

May 08, 2025

May 08, 2025

Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25 - marketscreener.com

May 08, 2025

May 08, 2025

MCRB: Seres Therapeutics' Price Target Raised by Chardan Capital | MCRB Stock News - GuruFocus

May 08, 2025

May 08, 2025

Chardan cuts Seres Therapeutics stock rating to neutral - Investing.com

May 08, 2025

May 08, 2025

Seres Therapeutics: Q1 Earnings Snapshot - Norwalk Hour

May 08, 2025

May 08, 2025

Seres Therapeutics Reports Positive Q1 2025 Results - TipRanks

May 08, 2025

May 07, 2025

Seres Therapeutics’ Positive Earnings Call: Progress and Challenges - TipRanks

May 07, 2025

May 07, 2025

Transcript : Seres Therapeutics, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com

May 07, 2025

May 07, 2025

Earnings call transcript: Seres Therapeutics Q1 2025 sees net income boost - Investing.com Nigeria

May 07, 2025

May 07, 2025

Seres Therapeutics, Inc. SEC 10-Q Report - TradingView

May 07, 2025

May 07, 2025

Seres Therapeutics Advances SER-155 Program with FDA Submission - TipRanks

May 07, 2025

May 07, 2025

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times

May 07, 2025

May 07, 2025

Seres Therapeutics (MCRB) Targets Advancement of SER-155 in Clinical Development | MCRB Stock News - GuruFocus

May 07, 2025

May 07, 2025

Seres Therapeutics Inc Qtrly EPS $3.76 - marketscreener.com

May 07, 2025

May 06, 2025

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 - The Globe and Mail

May 06, 2025

May 06, 2025

Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) PT at $80.00 - Defense World

May 06, 2025

May 05, 2025

Seres Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView

May 05, 2025

May 01, 2025

5 Best Microbiome Companies (May 2025) - Securities.io

May 01, 2025

May 01, 2025

Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com - Defense World

May 01, 2025

Apr 29, 2025

Seres Therapeutics Reveals Game-Changing Biomarkers for IBD Treatment, Seeks Development Partners - Stock Titan

Apr 29, 2025

Apr 29, 2025

Seres Therapeutics (MCRB) to Unveil New Findings at 2025 Digesti - GuruFocus

Apr 29, 2025

Apr 29, 2025

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases - The Manila Times

Apr 29, 2025

Apr 28, 2025

Investor’s Delight: Seres Therapeutics Inc (MCRB) Closes Weak at 0.70, Down -2.90 - DWinneX

Apr 28, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 25, 2025

Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - Defense World

Apr 25, 2025

Apr 24, 2025

MCRB Stock Update: Seres Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com

Apr 24, 2025

Apr 24, 2025

Seres Therapeutics Inc (MCRB) expanding its growth trajectory ahead - Sete News

Apr 24, 2025

Apr 24, 2025

Petri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock split - The Business Journals

Apr 24, 2025

Apr 23, 2025

Seres Therapeutics Reveals Q1 2025 Results: Live Biotherapeutics Pioneer Updates Growth Strategy - Stock Titan

Apr 23, 2025

Apr 22, 2025

Seres Therapeutics enacts 1-for-20 reverse stock split By Investing.com - Investing.com Canada

Apr 22, 2025